GlassScriptPhysician profile
Travis L Page
NPI 1396760385
$4,815.23
in general payments reported to CMS, 2019-2025
43 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $462 · 2021: $470 · 2022: $589 · 2023: $799 · 2024: $1,153 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.93 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,602.93 | 2021-2025 | |
| Pfizer INC. | $394.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.15 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $244.85 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $217.91 | 2020-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $179.71 | 2020 | |
| Lilly USA, LLC | $159.65 | 2019-2024 | Jardiance, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $127.84 | 2019-2021 | |
| Corcept Therapeutics | $126.90 | 2021-2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $92.83 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $91.90 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $85.93 | 2022-2024 | |
| Antares Pharma, INC. | $84.45 | 2025 | Xyosted |
| Amgen INC. | $83.83 | 2019-2025 | Evenity, Prolia |
| Vanda Pharmaceuticals INC. | $82.42 | 2024-2025 | Fanapt |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $75.05 | 2020-2024 | Trelegy Ellipta |
| Lundbeck LLC | $74.55 | 2022-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $70.56 | 2023-2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $58.78 | 2020-2024 | Farxiga |
| Abbott Laboratories | $50.39 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $49.42 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $48.92 | 2019-2021 | |
| Axsome Therapeutics, INC. | $42.84 | 2025 | Auvelity, Symbravo |
| Lucid Diagnostics INC. | $37.63 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.79 | 2021-2023 | Xifaxan |
| Impel Pharmaceuticals INC. | $36.47 | 2022 | |
| Merck Sharp & Dohme LLC | $32.45 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $31.54 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $27.55 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $27.06 | 2019-2021 | |
| Corium, LLC | $26.53 | 2022 | |
| Upsher-Smith Laboratories LLC | $24.95 | 2021 | |
| Viatris Specialty LLC | $23.31 | 2025 | Yupelri |
| Astellas Pharma US INC | $20.74 | 2024 | Veozah |
| Shield Therapeutics INC | $19.72 | 2024 | |
| Eisai INC. | $17.63 | 2021 | |
| Horizon Therapeutics Plc | $16.96 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.93 | 2023 | |
| Stryker Corporation | $15.68 | 2023 | Mako |
| Dexcom, INC. | $13.95 | 2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $13.66 | 2023 | Tirosint, Licart |
| Organon LLC | $13.25 | 2022 | |
| Idorsia Pharmaceuticals US INC | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.